Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556486 | 0.88 | LMNA (0.48) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL30664602 | 0.88 | LMNA (0.48) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL12726296 | 0.86 | MAPT (0.49) | CYP1A2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL6609945 | 0.85 | MTNR1A (0.49) | CYP1A2ALDH1A1LMNAKMT2ATHRB | |
| SCHEMBL3659178 | 0.85 | ALDH1A1 (0.57) | ALDH1A1GLAMEN1KMT2APOLB | |
| SCHEMBL2133926 | 0.84 | CYP1A2 (0.68) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL1626207 | 0.84 | PDGFRB (0.53) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL31001012 | 0.84 | PDGFRB (0.53) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL29777188 | 0.84 | CYP1A2 (0.68) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL16619742 | 0.82 | CYP1A2 (0.47) | CYP1A2PDGFRBFGFR1PDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092985-A1 | PHOSPHODIESTERASE 4B INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 合肥医工医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| CN-116514722-A | Benzimidazole derivatives as modulators of retinoic acid related orphan receptor gamma (ROR gamma) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3781161-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-3781161-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| CN-112135611-B | Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| EP-1237889-B1 | ANTIBIOTIC SULTAM AND SULTONE DERIVED OXAZOLIDINONES | UPJOHN CO (US) | 2004-09-01 | — | — | EP | disclosed |
| CN-1146564-C | Antibacterial sultam and sultone derived oxazolidinones | �������Ŷ���Լ��������˾ | 2004-04-21 | — | — | CN | disclosed |
| CN-1378546-A | Antibiotic sultam and sultone drived oxazolidiones | UPJOHN CO (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-1237889-A1 | ANTIBIOTIC SULTAM AND SULTONE DERIVED OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6420360-B1 | ANTIBIOTIC AGENTS. | PHARMACIA & UPJOHN COMPANY | 2002-07-16 | — | — | US | disclosed |
| US-20020055505-A1 | SULTAM AND SULTONE DERIVED OXAZOLIDINONES | ANDERSON DAVID JOHN (US) | 2002-05-09 | — | — | US | disclosed |
| US-6348459-B1 | DRUGS AND ANTIBIOTIC AGENTS. | PHARMACIA AND UPJOHN COMPANY | 2002-02-19 | — | — | US | disclosed |
| WO-2001032657-A1 | ANTIBIOTIC SULTAM AND SULTONE DERIVED OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055505-A1 | SULTAM AND SULTONE DERIVED OXAZOLIDINONES | SULT1A1, SULT1E1, SULT2A1 | CYP1A2 127/4885PDGFRB 3489/4885FGFR1 1345/4885 |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | RORC, RORB, RORA | CYP1A2 307/4885PDGFRB 147/4885FGFR1 296/4885 |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | CYP1A2 376/4885PDGFRB 142/4885FGFR1 2081/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | CYP1A2 295/4885PDGFRB 147/4885FGFR1 292/4885 |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | RORB, RORA, RORC | CYP1A2 279/4885PDGFRB 110/4885FGFR1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.